Study guide
26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome
Key Takeaways Explain This Topic AI
Tumour lysis syndrome causes hyperkalaemia, hyperphosphataemia, hyperuricaemia and hypocalcaemia, with acute kidney injury as the main complication.
Rasburicase is used for high-risk tumour lysis prophylaxis but is contraindicated in G6PD deficiency because it causes severe haemolysis.
PTH-related peptide-mediated hypercalcaemia shows a suppressed PTH with a raised calcium, distinguishing it from primary hyperparathyroidism.
Last updated: September 2026
4. Hypercalcaemia of Malignancy
Hypercalcaemia occurs in up to 30% of patients with advanced malignancy and carries a poor prognostic significance. Corrected serum calcium must always be calculated: Corrected Calcium = Measured Calcium + 0.02 × (40 - Serum Albumin [g/L]) . Mechanisms of Hypercalcaemia in Malignancy
- |
- +-----------------------------------+-----------------------------------+
- | | |
- 1. Humoral Hypercalcaemia 2. Local Osteolytic 3. 1,25-(OH)2-D Excess
- of Malignancy (~80%) Metastases (~20%) (<1%)
- Tumour-secreted PTHrP - Direct osteoclast activation - Tumour 1α-hydroxylase
- Squamous cell (lung, ENT), via RANKL, IL-1, IL-6, TNF-α - Hodgkin & non-Hodgkin
- renal cell, breast - Breast cancer, multiple myeloma lymphomas
- High Ca, Low PTH, High PTHrP - High Ca, Low PTH, Normal PTHrP - High Ca, Low PTH, High 1,25-D
- Pathophysiological Subtypes
Humoral Hypercalcaemia of Malignancy (HHM, ~80%): Mediated by tumour secretion of Parathyroid Hormone-related Protein (PTHrP) , which binds to parathyroid hormone 1 receptors (PTH1R) in bone and kidney, stimulating osteoclast bone resorption and renal tubular calcium reabsorption. Classically associated with squamous cell carcinomas (lung, oesophagus, cervix, head and neck) and renal cell carcinoma .
Local Osteolytic Hypercalcaemia (~20%): Extensive skeletal metastases secrete paracrine cytokines (RANKL, IL-1, IL-6, TNF-alpha) that trigger osteoclastic bone destruction. Classically seen in multiple myeloma and breast cancer .
1,25-Dihydroxyvitamin D (Calcitriol) Production (<1%): Autonomous expression of the enzyme 1-alpha-hydroxylase by malignant lymphoid tissue converts 25-hydroxyvitamin D to active calcitriol, driving massive gastrointestinal calcium absorption. Seen in Hodgkin and non-Hodgkin lymphomas .
Clinical Features
Renal: Polyuria, polydipsia (nephrogenic diabetes insipidus secondary to impaired ADH responsiveness in the medullary collecting duct), profound volume depletion, and nephrolithiasis.
Gastrointestinal: Anorexia, nausea, intractable vomiting, constipation, obstipation, and acute pancreatitis.
Neuromuscular: Muscle weakness, hyporeflexia, lethargy, cognitive slowing, delirium, psychosis, stupor, and coma.
Cardiovascular: Shortened QTc interval , widened T waves, J-point elevation, bradycardia, heart block, and ventricular arrhythmias.
Emergency Management Protocol
Aggressive Intravenous Rehydration (Cornerstone): Patients are severely hypovolaemic (fluid deficit 3–6 L). Infuse intravenous 0.9% sodium chloride 3 to 4 litres in the first 24 hours (e.g. 1 L over 2 hours, then 200–300 mL/hour, carefully monitoring fluid balance, urine output, and central venous pressure to prevent pulmonary oedema). Saline restores intravascular volume and induces renal calciuresis.
Intravenous Bisphosphonates: Administer IV zoledronic acid 4 mg in 100 mL 0.9% NaCl infused over 15 minutes (or pamidronate 60–90 mg over 2–4 hours). Bisphosphonates inhibit farnesyl pyrophosphate synthase in osteoclasts, inducing osteoclast apoptosis. Clinical Pearl: Bisphosphonates require 48 to 72 hours to exert clinical effect, with the nadir in serum calcium occurring at 4 to 7 days . Renal function must be checked; zoledronic acid requires dose adjustment in moderate renal impairment and is avoided in severe renal failure.
Denosumab: A fully human monoclonal antibody that binds and neutralizes RANKL , blocking osteoclast maturation. Dosed at 120 mg subcutaneously (with loading doses on days 8 and 15 in month 1). Indicated for bisphosphonate-refractory hypercalcaemia or severe renal impairment (no renal excretion).
Adjunctive Agents:
Salmon Calcitonin (4–8 IU/kg SC/IM every 12 hours): Rapid onset (lowers calcium within 2–4 hours by promoting renal excretion and inhibiting bone resorption), but exhibits rapid tachyphylaxis (receptor down-regulation) within 48 hours. Used as an emergency bridge in life-threatening hypercalcaemia (> 3.5 mmol/L) while awaiting bisphosphonate onset.
Corticosteroids (Prednisolone 40–60 mg/day): First-line therapy for lymphoma-mediated or granulomatous hypercalcaemia, as steroids directly inhibit 1-alpha-hydroxylase.
5. Tumour Lysis Syndrome (TLS)
Tumour lysis syndrome is an oncological emergency characterized by the massive, rapid breakdown of neoplastic cells and release of intracellular ions, nucleic acids, and proteins into the systemic circulation following cytotoxic chemotherapy, radiotherapy, or occasionally spontaneously.
High-Risk Malignancies
Haematological: Burkitt lymphoma, lymphoblastic lymphoma, diffuse large B-cell lymphoma (DLBCL), Acute Lymphoblastic Leukaemia (ALL), and Acute Myeloid Leukaemia (AML with hyperleukocytosis > 100 × 10⁹/L).
Solid Tumours: Rare, but occurs in bulky, highly chemosensitive tumours (small cell lung cancer, metastatic germ cell tumours, neuroblastoma).
The Metabolic Tetrad & Pathophysiology
Hyperkalaemia (> 6.0 mmol/L): Release of intracellular potassium; causes fatal ventricular arrhythmias and asystole.
Hyperphosphataemia (> 1.45 mmol/L): Malignant lymphoblasts contain up to 4 times more organic phosphate than normal leukocytes; causes hypocalcaemia and calcium phosphate crystal precipitation.
Hypocalcaemia (Corrected Calcium < 1.75 mmol/L): Secondary to rapid precipitation of insoluble calcium phosphate ( C a 3 ( P O 4 ) 2 Ca_3(PO_4)_2 C a 3 ( P O 4 ) 2 ) crystals in soft tissues and renal tubules; causes tetany, carpopedal spasm (Trousseau's sign), facial twitching (Chvostek's sign), laryngospasm, seizures, and prolonged QTc.
Hyperuricaemia (> 476 µmol/L): Catabolism of purine nucleic acids (adenine and guanine) via xanthine oxidase into uric acid; uric acid crystallizes in the acidic environment of renal collecting ducts, causing obstructive nephropathy and acute kidney injury (AKI) .
Cairo-Bishop Diagnostic Criteria
Diagnostic Category Criteria / Thresholds (Within 3 days before to 7 days after chemotherapy)
Laboratory TLS (LTLS) ; (Requires ≥ 2 criteria) • Uric Acid: ≥ 476 µmol/L (≥ 8.0 mg/dL) or 25% increase from baseline; • Potassium: ≥ 6.0 mmol/L or 25% increase from baseline; • Phosphate: ≥ 1.45 mmol/L (≥ 4.5 mg/dL) or 25% increase from baseline; • Calcium (Corrected): ≤ 1.75 mmol/L (≤ 7.0 mg/dL) or 25% decrease from baseline
Clinical TLS (CTLS) ; (LTLS plus ≥ 1 clinical complication) • Renal: Serum creatinine ≥ 1.5 × upper limit of age-adjusted normal, or oliguria; • Cardiac: Cardiac arrhythmia or sudden cardiac death; • Neuromuscular: Seizures, tetany, or altered mental state
Prophylaxis & Management Protocols
Vigorous Intravenous Hydration: High-volume hydration with 0.9% sodium chloride at 2.5–3.0 L/m²/day to maintain brisk diuresis (> 100 mL/m²/hour). CRITICAL PRACTICE PEARL: Urinary alkalinisation with sodium bicarbonate is no longer recommended ; while bicarbonate increases uric acid solubility, it markedly decreases calcium phosphate solubility, dramatically accelerating nephrocalcinosis and fatal renal failure, while worsening symptomatic hypocalcaemic tetany.
Hypouricaemic Pharmacotherapy:
Allopurinol (Xanthine Oxidase Inhibitor): Dosed 300 mg/m²/day (up to 500 mg daily). Prevents de novo formation of uric acid from hypoxanthine and xanthine. Limitation: Does NOT degrade pre-existing uric acid; requires 24–48 hours to attenuate urate levels. Indicated for low-to-intermediate risk TLS prophylaxis.
Rasburicase (Recombinant Urate Oxidase): Catalyses the enzymatic oxidation of uric acid into allantoin , an inert, highly water-soluble metabolite (5–10 times more soluble in urine than uric acid) that is readily excreted by the kidneys. Lowers uric acid levels within 4 hours. Indicated for established TLS or high-risk patients (Burkitt lymphoma, baseline uric acid > 450 µmol/L, high tumor burden).
CRITICAL CONTRAINDICATION: Rasburicase is strictly contraindicated in Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency . The enzymatic breakdown of uric acid generates hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 O 2 ); in G6PD-deficient erythrocytes deficient in NADPH and reduced glutathione, hydrogen peroxide induces catastrophic acute intravascular haemolytic anaemia and life-threatening methaemoglobinaemia (manifesting as cyanosis unresponsive to oxygen, Heinz bodies, and bite cells on blood film).
Electrolyte Management:
Hyperkalaemia: Immediate 10% calcium gluconate (10 mL IV over 10 minutes) for cardiac membrane stabilization, followed by nebulized salbutamol, IV regular insulin (10 units) in 50 mL 50% dextrose, and oral potassium binders (sodium zirconium cyclosilicate). Emergent continuous veno-venous haemofiltration (CVVHF) if refractory.
Hypocalcaemia Caution: Asymptomatic hypocalcaemia must NOT be treated with intravenous calcium, because infused calcium binds circulating phosphate, precipitating massive metastatic calcium phosphate deposition in the kidneys, myocardium, and lungs. Reserve IV calcium gluconate strictly for severe symptomatic hypocalcaemia (tetany, seizures, or life-threatening QTc prolongation).